2015 NCCN Annual Conference
Crystal S. Denlinger, MD, on Management of Anthracycline-Induced Cardiac Toxicity
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, discusses cardiac toxicities in cancer survivors, a new topic for the NCCN Survivorship Guidelines this year, and the need for more research on th...
Clifford Goodman, PhD, and Peter B. Bach, MD, MAPP, on Value-Based Decision-Making at the Bedside
Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, the “financial toxicities” of high drug...
Robert W. Carlson, MD, and William J. Gradishar, MD, on Optimizing Treatment of HER2-Positive Breast Cancer
Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the...
Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, ...
Samuel M. Silver, MD, PhD, and David S. Ettinger, MD, on the Characteristics of an Optimal Clinical Practice Guideline
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and David S. Ettinger, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss the evolutio...
Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed ...
Robert W. Carlson, MD, and Lee N. Newcomer, MD, MHA, on 20 Years of Improving Cancer Care Together: A Payer’s Perspective
Robert W. Carlson, MD, Chief Executive Officer of the National Comprehensive Cancer Network, and Lee N. Newcomer, MD, MHA, of UnitedHealthCare, discuss the value of NCCN Guidelines in determining cove...
Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN
Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early days of NCCN, controversies that surr...
John C. Grecula, MD, on the Role of Radiation Therapy in Management of SCLC
John C. Grecula, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of precision delivery of radiation fo...
Andrew J. Armstrong, MD, ScM, on New Treatment Options in Castration-Resistant Prostate Cancer
Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate...
Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer
Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer,...
Kenneth C. Anderson, MD, on Multiple Myeloma: Current Treatment Approaches and Future Directions
Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decad...
Thomas A. D’Amico, MD, on Diagnosis and Treatment of NSCLC Using Minimally Invasive Techniques
Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer surgeries in the Unite...
Anthony J. Olszanski, RPh, MD, on Immunotherapy and Melanoma
Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.
Rebecca H. Johnson, MD, on Fertility Preservation and Cancer
Although guidelines worldwide mandate fertility preservation for newly diagnosed patients within their reproductive window, most patients are still not referred or offered this option. Rebecca H. John...
Peter G. Shields, MD, on New NCCN Guidelines: Smoking Cessation for Patients With Cancer
Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for helping patients with ...
Peter E. Clark, MD, on a Guideline Update in the Management of Bladder Cancer
Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.
Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource avai...
Hans Gerdes, MD, on Endoscopic Therapies for Early-Stage Esophageal Cancers
Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.
Leora Horn, MD, MSc, on Targeted and Emerging Therapies for Metastatic NSCLC
Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials st...
Ingrid A. Mayer, MD, on New Therapies for Hormone-Sensitive Advanced Breast Cancer
Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.
Andrew D. Zelenetz, MD, PhD, on Emerging Treatment Options for Lymphomas
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzumab, ibrutinib, and o...
Melinda Telli, MD, on Evolving Treatment Strategies for Triple-Negative Breast Cancer
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
Gregory A. Otterson, MD, on Adjuvant Therapy and Immunotherapy for Lung Cancer
Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adj...
Amy Cyr, MD on Advances in Management of Early-Stage Breast Cancer
Amy Cyr, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, discusses advances made in the treatment of early-stage breast cancer: less radiation ...
Eric Jonasch, MD, on Kidney Cancer: Current and Novel Treatment Options
Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and ...
Mary Lou Smith, JD, MBA, on the Value of NCCN Guidelines to Patients and Their Advocates
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
William G. Wierda, MD, PhD, on Updates to the Management of CLL
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.
Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies
Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial ...
Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?
Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance discusses the evolution in treating and monitoring CML and whether monitoring at 3 and 6 months wil...
John A. Thompson, MD, on Treatment Options for Advanced Melanoma
John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembrolizumab, trametinib...
